Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer

Immutep Limited (NASDAQ: IMMP) has

Benzinga

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has

Benzinga

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus

Amryt Pharma Plc's (NASDAQ:AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin revenues that increased 44% to $31.9 million. Cash of $113 million at December 31, 2021 (2020: $118.8M) The Company reported a wider operating loss of $(50.5) million…

Benzinga

Renalytix Launches National Physician Access To KidneyIntelX Platform

Renalytix plc (NASDAQ:RNLX) has launched its new provider access portal, myIntelX, to provide nationwide online access for physicians to order KidneyIntelX bioprognostic testing. KidneyIntelX enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including blood-based biomarkers and personalized health data. It employs a proprietary algorithm to generate a…

Benzinga

Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the back burner.

Benzinga

Enforcing Abortion Bans Is Much Harder Than Passing Them

The experience in Texas shows that workarounds pose daunting obstacles to such laws.

Reason

Read news from The Economist, FT, and more,
with one subscription

Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy

Michael Mullette, a former Moderna (NASDAQ:MNRA) vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient…

Benzinga

This Microcap Pharma Stock Almost Doubled Today - Read Why

UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ:KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. Eysuvis now has coverage for approximately 118 million lives or 70% of all commercial lives. Kala also announced that Cigna Medicare had added Eysuvis as a preferred brand effective…

Benzinga

Congress Seems Poised To Let the FDA Ban E-Cigarettes Containing Synthetic Nicotine

A spending bill provision would redefine "tobacco products" to include products that have nothing to do with tobacco.

Reason

Read Why Valneva's Stock Gained 7% Today

Valneva SE (NASDAQ:VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. The removal of two subjects from the analysis increased the proportion of participants with protective…

Benzinga

Why Owlet Shares Are Trading Lower Today

Owlet Inc (NYSE:OWLT) reported FY21 sales of 75.8 million, just 0.6% higher than the $75.4 million reported a year ago. The Company noted that through the first three quarters of 2021, revenues were $78.4 million, up 44% Y/Y, but early in Q4 FY21, Owlet received an FDA Warning Letter, resulting in halting sales…

Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Can the FDA's New Commissioner Save the Agency From Itself?

Robert Califf must demand transparency and accountability from the bureaucrats.

Reason

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients

The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and

Benzinga

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System

The

The Hindu

Gene-edited beef cattle get regulatory clearance in U.S.

Meat from gene-edited cattle could be on the way in a few years

Benzinga

Lung-Disease Focused AN2 Therapeutics Files Plans For NASDAQ Debut

AN2 Therapeutics Inc filed plans on Friday to go public in an initial public offering in which it reportedly hopes to raise about $75 million. AN2 plans to list on the Nasdaq with the symbol of ANTX. The Menlo Park-based biotech is developing a therapy for non-tuberculous mycobacterial (NTM) lung disease, which…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial

LAVA Therapeutics NV (NASDAQ:LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first three cohorts of the LAVA-051 Phase 1/2a trial, along with preclinical data on its two lead programs, LAVA-051 and LAVA-1207. The first three dose-escalation cohorts showed LAVA-051 to be safe and…

Benzinga

Why Alpine Immune's Shares Are Falling Today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ:ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of patient death in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and…

Benzinga

NOVN: A Banner Year for Novan - 2021 Results

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

StockNews.com

Is Ra Medical Systems a Good Penny Stock to Own?

The shares of commercial-stage medical device maker Ra Medical Systems (RMED) have tumbled 92.7% in price over the past year due to investor concerns surrounding the company’s poor financial health. Also, given the uncertainty surrounding the FDA’s approval of its DABRA catheter laser system, the question becomes, is the penny…

Zenger

Electrical Stimulation Zaps Premature Ejaculation

FDA-approved vPatch can prolong the time to orgasm by a factor of three and a half. The disposable patch will cost about $15.

Bangkok Post

Local Covid vaccines undergo human trials

Four out of more than 20 Covid-19 vaccine candidates being developed in Thailand are now being tested on humans, the final process required before they are submitted for approval by the Food and Drug Administration (FDA), the government said on Saturday.

Benzinga

Analysts Move To Sidelines On Vicarious Surgical After Regulatory Update

Piper Sandler has downgraded Vicarious Surgical Inc (NASDAQ:RBOT) to Neutral from Overweight with a price target of $7, down from $16, below expected Q4 results. A majority of the earnings call focused on the Company's regulatory update. Vicarious announced its plans to pursue a De Novo FDA pathway, including a pre-market study, for its…

1 … 250 251 252 253

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.